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Background. Single-nucleotide polymorphisms in genes involved in lipoprotein and adipocyte metabolism
may explain why dyslipidemia and lipoatrophy occur in some but not all antiretroviral therapy (ART)–treated
individuals.
Methods. We evaluated the contribution of APOC3 482CrT, 455TrC, and 3238CrG; 2 and 4 alleles
of APOE; and TNF 238GrA to dyslipidemia and lipoatrophy by longitudinally modeling 12600 lipid deter-
minations and 2328 lipoatrophy assessments in 329 ART-treated patients during a median follow-up period of
3.4 years.
Results. In human immunodeficiency virus (HIV)–infected individuals, the effects of variant alleles of APOE
on plasma cholesterol and triglyceride levels and of APOC3 on plasma triglyceride levels were comparable to those
reported in the general population. However, when treated with ritonavir, individuals with unfavorable genotypes
of APOC3 or APOE were at risk of extreme hypertriglyceridemia. They had median plasma triglyceride levels of
7.33 mmol/L, compared with 3.08 mmol/L in the absence of ART. The net effect of the APOE*APOC3*ritonavir
interaction was an increase in plasma triglyceride levels of 2.23 mmol/L. No association between TNF 238GrA
and lipoatrophy was observed.
Conclusions. Variant alleles of APOE and APOC3 contribute to an unfavorable lipid profile in patients with
HIV. Interactions between genotypes and ART can lead to severe hyperlipidemia. Genetic analysis may identify
patients at high risk for severe ritonavir-associated hypertriglyceridemia.
Adverse metabolic effects of potent antiretroviral ther-
apy (ART) have become a major concern. Hyperlipi-
demia increases the risk of cardiovascular disease [1].
Lipoatrophy may stigmatize the patient and is associ-
ated with insulin resistance and hyperlipidemia [2, 3].
Both hyperlipidemia and lipoatrophy have been linked
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to advancing age, male sex, a CD4 T cell count !200
cells/mL, and the type of ART used [2,4]. The use of
ritonavir (RTV) and RTV-boosted protease inhibitors
(PIs) are the most significant predictors of hypercho-
lesterolemia and hypertriglyceridemia [4], whereas use
of stavudine (d4T), didanosine (ddI), and, in some
studies, PIs are associated with lipoatrophy [2]. How-
ever, these complications do not occur in all patients,
despite similar exposure to ART and comparable de-
mographic, immunologic, and virologic characteristics.
The reasons for this discrepancy may be related to host
genetic factors.
Single-nucleotide polymorphisms (SNPs) in APOE
(specifically the APOE 4 and 2 alleles) are linked to
hyperlipidemia and cardiovascular events [5] in the
general population. SNPs of APOC3 at positions455
and 482 in the promoter region and at position 3238
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Table 1.
The table is available in its entirety in the online
edition of the Journal of Infectious Diseases.
in the 3′ untranslated region (the SstI allele) are associated with
hypertriglyceridemia [6, 7]. A SNP at position 238 in the
promoter region of TNF (previous designation, TNF-a) has
been linked to the more-rapid onset of lipoatrophy in ART-
treated patients [8], and the rare allele was found to be present
more frequently in patients with HIV who have lipoatrophy
than in those who do not have the condition [9]. The APOE
genotype may be functionally associated with hyperlipidemia,
as the role of APOE in the transport and clearance of lipo-
protein remnants from the bloodstream would suggest [5].
Through the inhibition of the activity of lipoprotein lipase,
APOC3 modulates lipolysis and hepatic clearance of plasma
triglycerides (TGs) [6, 7]. TNF expression in adipose tissue has
been implicated in lipoatrophy because of its modulation of
lipolysis and adipocyte differentiation [10]. Most reports on
the metabolic complications associated with APOE and APOC3
polymorphisms have been based on studies of the general pop-
ulation. In HIV-infected individuals, the interpretation of the
data has been limited by the small number of patients studied
[11, 12], contradictory findings regarding a link between APOE
genotype and hyperlipidemia [12–14], and a focus on PI-treated
men [13–15]. The present study used a longitudinal approach
to model the influence of APOE and APOC3 polymorphisms
on ART-associated hyperlipidemia, as well as the influence of
the TNF 238 polymorphism on lipoatrophy, in the context
of frequent changes of therapy and other contributing factors.
PATIENTS AND METHODS
Patients. Study participants were followed in the Swiss HIV
Cohort Study (SHCS) (http://www.shcs.ch) and were treated
for HIV infection at 1 of 7 Swiss medical centers. The genetics
project of the SHCS was approved by the ethics committees of
all participating centers. Patients were included if they had given
written, informed consent for genetic testing.
Lipid determinations included the routine assessments of
plasma total cholesterol, high-density lipoprotein (HDL) cho-
lesterol, and TG levels. The level of non-HDL cholesterol
(NHC) was calculated by subtracting the level of HDL choles-
terol from the level of total cholesterol. Patients who had a
Centers for Disease Control and Prevention stage C AIDS-de-
fining event in the preceding 3 months or a CD4 T cell count
!100 cells/mL were excluded, to limit confounding by HIV-
associated wasting and opportunistic illness. Lipoatrophy was
defined by the patient-reported presence of fat loss at1 body
site (face, neck, arms, legs, or buttocks) that was confirmed by
the physician on physical examination. No lipoatrophy assess-
ments were made by use of computed tomography scanning
or dual-energy x-ray absorptiometry. The fasting state (with
fasting defined as 8 h without caloric intake) was recorded
each time that a blood sample was taken.
Allelic discrimination. Genomic DNA was extracted from
frozen leukocyte pellets. APOC3 promoter482CrT [7], APOC3
3′UTR 3238CrG [7], APOE coding region 2060TrC [5], and
TNF promoter 238GrA [8, 9] were investigated by TaqMan
allelic discrimination (Applied Biosystems) (table 1). The poly-
morphisms of APOC3 455TrC, APOE 2060TrC, and APOE
2198CrT were assessed by PCR amplification and restriction
fragment–length polymorphism (RFLP) analysis using either
FokI [13, 16] or HhaI [17] digestion. All equivocal results were
repeated and confirmed by a second observer. Results were
entered into the central SHCS database in a blinded fashion.
For statistical analysis, all variant alleles were assessed indi-
vidually, and, for the purpose of clarity, were reported using
previously reported composite genotypes [13, 18]. For analysis
of plasma TG levels [18], we assessed (1) the presence of APOE
3/3 versus 2-containing APOE genotypes (i.e., 2/2, 2/
3, and 2/4) versus APOE 3/4 and APOE 4/4, as well
as (2) APOE 3/3 versus all alleles other than 3/3. For the
analysis of plasma cholesterol levels [18], we assessed APOE 3/
3 versus 2-containing APOE genotypes (i.e., 2/2, 2/3, and
2/4) versus APOE 3/4 and APOE 4/4. For APOC3, the
cumulative number of variant alleles was used, as reported else-
where [13], and thus we assessed common alleles, 1 or 2 variant
alleles, and all 3 variant alleles.
Statistical analysis. The data were analyzed longitudinally
by modeling the individual effects of the different covariables on
plasma lipid levels and on body fat loss. The study period was
defined as the follow-up period beginning after the first study
visit that included measurement of plasma lipid levels (available
since 1999) until 22 March 2004, when information from the
SHCS database was downloaded. The analysis used a well-estab-
lished statistical method developed for longitudinal data analysis,
population-averaged marginal modeling [19, 20]. A multivariate
distribution was fitted to the data by use of score-like methods
(generalized estimating equations) [19, 20]. The advantages of
this approach include the ability to accommodate repeated mea-
surements at irregular intervals, the straightforward interpreta-
tion of regression coefficients, and the computational efficiency
for relatively large data sets. Covariables included in the regres-
sion model were ART regimen, age, sex, body mass index (BMI),
waist circumference, fasting state, presumed mode of HIV trans-
mission, ethnicity, diabetes mellitus status, treatment with lipid-
lowering agents, smoking status, CD4 T cell count, HIV load,
and the genetic factors tested. The influence of ART and of lipid-
lowering agents on plasma lipid levels was assumed to be rapid
and reversible [21]. For evaluation of the effects of the genetic
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Table 2. Patient characteristics.
Characteristic Study participants
( )np 329
SHCS participants
( )np 6724
Baseline age, median (IQR), years 39.8 (35.5–47.3) 38.2 (33.3–44)
Men/women, no. (% men) 261/68 (79.3) 4619/2105 (68.7)
Ethnicity, no. (%)
White 289 (87.8) 5290 (78.7)
Black 23 (7) 690 (10.3)
Hispanic 9 (2.7) 116 (1.7)
Asian 6 (1.8) 186 (2.8)
Unknown/other 2 (0.6) 442 (6.6)
CD4 T cell count, median (IQR), cells/mL
Baseline 407 (256–602) 399 (237–592)
During follow-up period 443 (298–629) 426 (275–614)
Presumed mode of HIV transmission, no. (%)
Homosexual sex 139 (42.2) 2232 (33.2)
Heterosexual sex 113 (34.3) 2476 (36.8)
Intravenous drug use 61 (18.5) 1773 (26.3)
Unknown 16 (4.9) 243 (3.6)
Viral load, no (%) with !400 RNA copies/mL
Baseline 246 (80.3) 3276 (51.8)
During follow-up period 2182 (84) 22,575 (64.5)
Follow-up period
Duration, median (IQR), years 3.4 (3.2–3.6) 2.8 (1.2–3.4)
Dropouts during, no. (%) 7 (2.1) 1099 (16.3)
Deaths during, no. (%) 2 (0.6) 380 (5.6)
Treated with lipid-lowering agents, no. (%) 48 (14.6) 580 (8.6)
Diabetes mellitus, no. (%) 15 (4.6) 166 (2.5)
Plasma HDL cholesterol level during follow-up period, median (IQR), mmol/L 1.2 (0.9–1.4) 1.2 (0.9–1.4)
Plasma non-HDL cholesterol level during follow-up period, median (IQR), mmol/L 4.1 (3.2–5) 3.8 (3–4.7)
Plasma triglyceride level during follow-up period, median (IQR), mmol/L 2 (1.3–3.2) 1.7 (1.1–2.8)
Assessments at which lipoatrophy was present during follow-up period, no. (%) 519 (26.8) 5254 (20.5)
NOTE. HDL, high-density lipoprotein; IQR, interquartile range; SHCS, Swiss HIV Cohort Study.
variants on lipoatrophy, the cumulative exposure to ART was
used, as was reported elsewhere [2, 22].
Exploratory analyses confirmed the published effects of in-
dividual ART agents on plasma HDL cholesterol, NHC, and
TG levels and on lipoatrophy [3, 4, 23]. These data supported
the rationale for dividing the ART regimens into the following
groups: (1) no ART at the time that a blood sample was taken,
(2) PI-sparing ART, (3) single-PI ART, and (4) RTV-containing
ART. For lipoatrophy analysis, the ART regimens were divided
into the following groups [2, 22]: (1) ART that did not include
ddI, d4T, or a PI; (2) ART that included ddI and/or d4T but
no PI; (3) ART that included a PI but not ddI or d4T; and (4)
ART that included ddI and/or d4T and a PI.
When the date of the assessment of plasma lipid levels did
not coincide with that of the assessment of waist circumference
and weight, the values of these latter covariables were imputed
by linear interpolation at the date of the assessment of plasma
lipid levels. For appropriate confounding adjustment, cross-
sectional and longitudinal relationships between the continuous
explanatory variables and the response were distinguished [20,
24, 25]. Adequate functional form was assessed using fractional
polynomials [26, 27]. The correlation structure was assumed
to be autoregressive [19], because the clustering was at the
individual level (repeated measurements). However, when other
(e.g., exchangeable) correlation structures were used, the results
were similar. Goodness of fit was evaluated visually by com-
paring mean observed and predicted measurements on time
plots of values in strata defined by polymorphisms and ART
group [20].
For analysis of lipoatrophy, the dependent variable was bi-
nary, and the logit link was used. The correlation structure was
assumed to be exchangeable, because exploratory analyses in-
dicated that lipoatrophy was rarely reversible over the follow-
up period. A robust sandwich estimate of variances-covariances
was used, which produces valid SEs even if the correlation
structure was misspecified [19, 20].
Two-way as well as 3-way interactions between genotypes and
ART groups were first tested globally. If the global test was sig-
nificant, subcategories contributing to the P value were screened
for, and significant and consistent strata were retained. The re-
grouping of subcategories into strata was performed using the
global x2 test, to address the issue of multiple comparisons.
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Table 3. Multivariate analysis of the contribution of demographic factors, antiretroviral therapy (ART), and variant alleles of APOE
and APOC3 to hyperlipidemia in 329 study participants.
Effect on plasma level
HDL
cholesterol
Non-HDL
cholesterol Triglycerides
Variable
Mean (95% CI)
change, mmol/L P
Mean (95% CI)
change, mmol/L P
Mean (95% CI)
change, mmol/L P
Baseline age (change per year) 0.01 (0.02 to 0.002) .025 0.07 (0.04 to 0.10) !.001 0.04 (0.01 to 0.08) .101
Male sex 0.18 (0.3 to 0.06) .004 0.09 (0.45 to 0.26) .610 0.36 (0.85 to 0.13) .153
Fasting state 0.01 (0.03 to 0.02) .500 0.05 (0.03 to 0.14) .219 0.18 (0.37 to 0.02) .073
ART
PI sparing 0.11 (0.03–0.17) .006 0.27 (0.49 to 0.04) .019 0.23 (0.29 to 0.75) .381
Single PI 0.06 (0.01 to 0.13) .080 0.29 (0.07–0.52) .010 0.20 (0.31 to 0.71) .448
RTV containing 0.01 (0.08 to 0.07) .823 0.65 (0.41–0.89) !.001 1.71 (1.16–2.25) !.001
Treated with lipid-lowering agents 0.03 (0.98 to 0.03) .298 0.29 (0.50 to 0.09) .005 0.60 (0.20–0.99) .003
APOE genotype
2/2, 3/2, and 4/2 0.04 (0.16 to 0.07) .467 0.02 (0.30 to 0.33) .917 NA …
3/4 and 4/4 0.06 (0.15 to 0.04) .236 0.27 (0.02–0.53) .038 NA …
All genotypes other than 3/3 NA … NA … 0.73 (0.41–1.04) .001
APOC3 genotype
1 or 2 variant alleles 0.26 (0.05 to 0.11) .523 0.19 (0.40 to 0.03) .088 0.03 (0.28 to 0.35) .828
All 3 variant alleles 0.03 (0.07 to 0.14) .534 0.27 (0.55 to 0.002) .052 0.57 (0.16–0.98) .006
NOTE. The reference for the regression model represents a mean plasma HDL cholesterol level of 1.25 mmol/L (95% confidence interval [CI], 1.05–1.44), a
mean non–high density lipoprotein (HDL) cholesterol level of 4.87 mmol/L (95% CI, 4.33–5.42), and a mean plasma triglyceride level of 1.57 mmol/L (95% CI, 0.78–
2.35) for a 43-year-old woman whose plasma lipid levels were assessed in the nonfasting state, had a body mass index (BMI) of 23 kg/m2, had a waist circumference
of 85 cm, had a CD4 T cell count of 500 cells/mL, had a viral load of 1.7 log10 copies/mL, was white, was not diabetic, was a nonsmoker, was not being treated
with ART, was not being treated with lipid-lowering agents, was transmitted HIV by heterosexual sex, and had the common APOE and APOC3 genotypes. Values
are adjusted for all the variables shown, as well as for diabetes mellitus status, ethnicity, smoking status, BMI, waist circumference, and viral load. For continuous
variables, the effect on the plasma lipid level of each variable represents the impact of a 1-unit increase. For categorical variables, the effect represents the impact
that the indicated variable has on plasma lipid levels compared with the reference value. NA, not applicable; PI, protease inhibitor; RTV, ritonavir.
Patients who had elevated plasma HDL cholesterol, NHC,
and TG levels were matched by age (5 years), BMI (3
units), sex, and ART group to patients who had normal values
for these lipid parameters, and a single-time-point, cross-sec-
tional analysis was performed. All statistical analyses were con-
ducted using Stata (version 8.2; StataCorp).
RESULTS
Patients. The clinical characteristics of the study patients
( ) are summarized in table 2. We compared their char-np 329
acteristics with those of the entire population of patients en-
rolled in the SHCS who had 1 follow-up visit during 1999–
2003 ( ). Compared with this population of the SHCS,np 6724
the study patients were more likely to have suppressed HIV
viremia, the duration of their follow-up period was longer, and
there were fewer deaths and dropouts. These characteristics
define the selection bias of patients in the SHCS Genetic Co-
hort, who were chosen for the quality of their clinical docu-
mentation and their ability to sign the consent form for genetic
analysis.
The allelic frequencies were as follows: APOC3 455TrC,
0.410; APOC3482CrT, 0.303; APOC3 3238CrG, 0.092; APOE
2060TrC, 0.093; APOE 2198CrT, 0.055; and TNF 238GrA,
0.035. These were comparable to the published allelic frequen-
cies in ethnically similar populations [28]. The distribution of
the genotypes was as follows: APOE 3/3, 238 patients (72.3%);
APOE genotypes other than 3/3, 91 patients (27.7%; 2/2,
2/3, or 2/4, 35 patients [10.6%]; 3/4 or 4/4, 56 patients
[17.0%]); common alleles of APOC3, 120 patients (36.5%); 1
or 2 variant alleles of APOC3, 150 patients (45.6%); and all 3
variant alleles of APOC3, 59 patients (17.9%).
During the follow-up period, a total of 2608 determinations
of plasma cholesterol (both HDL and NHC) levels (mean, 7.4
determinations of plasma cholesterol levels/patient) and 2741
determinations of plasma TG levels (mean, 7.8 determinations
of plasma TG levels/patient) were recorded (range, 3–18 total
lipid determinations/patient). The mean number of determi-
nations of plasma TG levels during the follow-up period was
comparable in subjects with low and high median plasma TG
levels (patients with low median plasma TG levels, 7.97 deter-
minations/patient; patients with high median plasma TG levels,
8.25 determinations/patient); the median number of deter-
minations was identical (7 determinations/patient). Thus, po-
tential bias due to overrepresentation of subjects with high
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Table 4. Interactions between genotypes and antiretroviral
therapy (ART).
Interaction
Plasma level
HDL
cholesterol
Non-HDL
cholesterol Triglycerides
ART*APOE .799 .087 .474
ART*APOC3 .202 .100 .233
APOE*APOC3 .738 .197 .025a
ART*APOE*APOC3 .584 .173 .003b
NOTE. All data are P values as determined by global x2 test. HDL, high-
density lipoprotein.
a The only genotype category that contributed significantly was APOE ge-
notypes other than 3/3, in association with all 3 variant alleles of APOC3.
b The only ART category that contributed significantly was ART containing
ritonavir in patients who have APOE genotypes other than 3/3 in association
with all 3 variant alleles of APOC3.
Figure 1. Effect of genotype–antiretroviral therapy (ART) interactions on adjusted plasma triglyceride (TG) levels. The medians plus interquartile ranges
(boxes) and upper and lower adjacent values (whiskers) show the adjusted distribution of plasma TG levels. The median (black horizontal line) and estimated
range (gray horizontal stripe) of plasma TG levels for patients receiving no ART regimen who have common APOE or APOC3 alleles is shown. Patients
are grouped according to the number of variant alleles of APOC3 they have (none, 1 or 2 variant alleles, or all 3 variant alleles), and patients who have
the common APOE 3/3 genotype (gray boxes) are compared with patients who have APOE non-3/3 genotypes (white boxes). PI, protease inhibitor;
RTV, ritonavir.
plasma TG levels is unlikely. The median plasma lipid levels
during the follow-up period are shown in table 2. Results were
unchanged when plasma lipid levels in patients who had an
AIDS-defining event in the preceding 3 months or a CD4 T
cell count !100 cells/mL were included.
Effects of ART regimen on plasma lipid levels. There were
a total of 9169 determinations of the type of ART regimen in
use during the study period. No ART was in use at 1078 (11.8%)
time points. PI-sparing ART, single-PI ART, and RTV-contain-
ing ART were in use at 2965 (32.3%), 3242 (35.4%), and 1884
(20.5%) time points, respectively. The influence of ART regi-
men on plasma lipid levels is summarized in table 3. The pop-
ulation-averaged plasma HDL cholesterol level was higher in
patients treated with PI-sparing ART ( ). The plasmaPp .006
NHC level was lower in patients treated with PI-sparing ART
( ) and higher in patients treated with single-PI ARTPp .019
( ) or RTV-containing ART ( ). Plasma TG levelsPp .01 P ! .001
were significantly higher only in patients treated with RTV-
containing ART ( ). Because RTV can be used at dif-P ! .001
ferent dosages, we compared plasma TG levels in patients
treated with RTV alone (600 mg of RTV twice daily) or in
combination with lopinavir (100 mg of RTV twice daily) or
saquinavir (400 mg of RTV twice daily). The median plasma
TG levels during the follow-up period in these 3 groups of
patients were comparable (3.19 vs. 3.00 vs. 2.89 mmol/L, re-
spectively; ). Thus, patients treated with RTV were an-Pp .63
alyzed as a single group. As was reported elsewhere [29], there
was a trend toward higher mean plasma TG levels in patients
treated with PI-sparing ART that contained efavirenz (0.47
mmol/L [95% confidence interval {CI}, 0.08 to 1.02 mmol/
L] increase in plasma TG levels; ).Pp .09
Effects of variant alleles on plasma TG levels. APOE ge-
notypes other than the common 3/3 genotype were associ-
ated with higher mean plasma TG levels ( ) (table 3).P ! .001
The increase in plasma TG levels was 0.9 mmol/L (95% CI,
0.43–1.36 mmol/L) ( ) for APOE genotypes 2/2, 3/P ! .001
2, and 4/2 and was 0.61 mmol/L (95% CI, 0.23–1.00 mmol/
L) ( ) for APOE genotypes 3/4 and 4/4. Thus, asPp .002
1424 • JID 2005:191 (1 May) • Tarr et al.
Table 5. Adjusted contribution of demographic factors, antiretro-
viral therapy (ART), and genotypes to lipoatrophy in study participants.
Variable Odds ratio (95% CI) P
Baseline age, increase per year 1.042 (1.013–1.071) .004
Female sex 0.508 (0.235–1.096) .084
Cumulative exposure to ART, per month
No ddI or d4T or PI 1.000 (0.988–1.011) .999
ddI and/or d4T but no PI 1.035 (1.018–1.053) !.001
PI but no ddI or d4T 1.009 (0.997–1.021) .153
ddI and/or d4T and PI 1.021 (1.009–1.033 !.001
BMI at baseline, increase per point 0.719 (0.55–0.941) .016
Waist circumference, increase per cm 1.148 (1.046–1.26) .004
APOE genotype
2/2, 3/2, or 4/2 1.464 (0.73–2.939) .283
3/4 or 4/4 1.152 (0.621–2.138) .653
APOC3 genotype
1 or 2 variant alleles 1.044 (0.623–1.751) .870
All 3 variant alleles 1.870 (1.013–3.453) .046
TNF 238GrA 1.261 (0.494–3.215) .625
NOTE. Multivariate analysis, adjusted for time (increase in age), diabetes
mellitus status, ethnicity, smoking status, body mass index (BMI), waist cir-
cumference, and viral load. CI, confidence interval; d4T, stavudine; ddI, didano-
sine; PI, protease inhibitor.
regards plasma TG levels, APOE genotypes other than 3/3
were analyzed as a single group. Plasma TG levels were sig-
nificantly elevated in patients who had all 3 variant alleles of
APOC3 ( ) but not in patients who had only 1 or 2Pp .006
variant alleles of APOC3 ( ).Pp .83
The most unfavorable composite genotype consisted of APOE
genotypes other than 3/3 plus all 3 variant alleles of APOC3
(table 4). The predicted net effect of the APOE*APOC3 inter-
action was a mean 1.24 mmol/L (95% CI, 0.45–2.03 mmol/L)
increase in plasma TG levels ( ). This unfavorable com-Pp .02
posite genotype was associated with elevations of plasma TG
levels in patients in all ART groups; however, the most striking
genotype-ART interaction was observed when patients who had
the unfavorable composite genotype were treated with RTV-
containing ART (figure 1). Here, the predicted net effect of the
APOE*APOC3*RTV interaction was a mean 2.23 mmol/L (95%
CI, 1.33–3.14 mmol/L) increase in plasma TG levels ( ).P ! .001
These estimates represent the contribution of the interactions
in addition to the specific effects of the covariables listed in
table 3. Thus, the mean plasma TG level in patients who had
the unfavorable composite genotype was 3.08 mmol/L if no
ART was used and increased to 7.33 mmol/L when RTV was
used in the regimen ( ) (figure 1).P ! .001
When patients were exposed to RTV, extreme hypertriglyc-
eridemia (defined as at least 2 determinations at which plasma
TG levels were above the 95th percentile of the study population
[7.0 mmol/L]) was recorded in 4 (15.4%) of 26 patients who
had common alleles of APOE and APOC3, in 3 (20.0%) of 15
patients who had all 3 variant alleles of APOC3 and common
alleles of APOE, in 1 (11.1%) of 9 patients who had APOE non-
3/3 genotypes and common alleles of APOC3, but in 6 (60.0%)
of 10 patients who had the unfavorable composite genotype
( ). The TNF 238GrA polymorphism had no effectPp .026
on plasma TG levels ( ).Pp .973
An additional, single-time-point, cross-sectional analysis of
75 patients who had plasma TG levels 2.3 mmol/L and 75
control subjects who had normal plasma TG levels and were
matched to patients by age, BMI, sex, and ART group was
underpowered for detection of the deleterious effects of variant
alleles of APOC3 or APOE. For example, individuals who had
APOE non-3/3 genotypes had an odds ratio of 1.41 (95%
CI, 0.65–3.06) for the development of hypertriglyceridemia
( ).Pp .379
Effects of variant alleles on plasma NHC and HDL choles-
terol levels. The 3/4 and 4/4 APOE genotypes were as-
sociated with elevated plasma NHC levels ( ) (table 3).Pp .038
As expected, the APOE genotype had no influence on plasma
HDL cholesterol levels. There was a trend toward lower plasma
NHC levels in patients who had 1 or 2 variant alleles of APOC3
( ) and in patients who had all 3 variant alleles (Pp .088 Pp
). No significant interaction between various genotypes and.052
ART group were identified (table 4). No effect of the TNF
238GrA polymorphism on either plasma HDL cholesterol
levels or plasma NHC levels was seen ( and Pp .881,Pp .592
respectively).
Lipid-lowering agents were given more frequently to patients
who had APOE genotypes other than 3/3 (12.2% of deter-
minations) and to patients who had variant alleles of APOC3
(10.8% of determinations) than to patients who had the APOE
3/3 genotype (8.7% of determinations) ( ) or to pa-Pp .007
tients who had the common alleles of APOC3 (7.6%) (Pp
); the models were adjusted for treatment with lipid-low-.023
ering agents.
Lipoatrophy. A total of 2328 assessments of lipoatrophy
(mean, 7.1 assessments/patient; range, 3–9 assessments/patient)
were made during the follow-up period in 325 patients. The
prevalence of lipoatrophy was 25.2%. Baseline age ( ),Pp .004
BMI ( ), and waist circumference ( ) were as-Pp .016 Pp .004
sociated with lipoatrophy (table 5). Lipoatrophy was associated
with cumulative exposure to ddI/d4T, irrespective of the as-
sociated use of a PI ( ). Exposure to a PI in the absenceP ! .001
of ddI and/or d4T was not associated with lipoatrophy (Pp
). The odds ratio for the development of lipoatrophy was.153
higher in patients who had 3 variant alleles of APOC3 (Pp
.046) but was not higher in patients who had the TNF238GrA
polymorphism ( ).Pp .625
DISCUSSION
We report on the identification of a significant genotype-ART
interaction that may lead to severe hyperlipidemia in HIV-
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infected patients treated with ART. Known genetic variants in
APOC3 and APOE contributed significantly to elevations in
plasma TG levels to a degree comparable to factors such as age
or the use of RTV-containing ART. However, the effect of un-
favorable APOC3 alleles was observed only in patients who
received ART. Variant alleles of APOC3 and APOE had no
significant effect on plasma HDL cholesterol levels, whereas the
effect of variant alleles of APOE on plasma NHC levels was
additive to that of single-PI ART. Our results extend the findings
reported by Fauvel et al. [13], who documented an association
between variant alleles of APOC3 and hypertriglyceridemia in
60 men treated with PIs.
The most relevant finding of our study is the identification
of a complex genotype-ART interaction that may lead to ex-
treme hypertriglyceridemia when individuals with an unfavor-
able composite APOC3-APOE genotype are exposed to RTV.
Such a phenotypic expression of a latent genetic predisposition
to hyperlipidemia has been reported by Rodondi et al. [18]. In
this pharmacogenetic study, these authors identified an elevated
risk of future hyperlipidemia in APOE 2 and 4 carriers who
developed hypertriglyceridemia during retinoic acid treatment
for acne. Conversely, patients who did not have elevations in
their plasma TG levels during retinoic acid therapy seemed to
be protected against future hyperlipidemia.
We did not identify a genetic predisposition to lipoatrophy
in patients in our data set who had the TNF 238GrA poly-
morphism. This is in contrast to the findings of 2 other studies
[8, 9]. Nolan et al. [8] used a time-to-event model to evaluate
the occurrence of lipoatrophy in 191 white men. The frequency
of the rare allele ( ) was higher than that in the presentfp 0.065
study ( ). After 2 years of follow-up, the effect of thefp 0.035
TNF polymorphism was modest in the study by Nolan et al.,
but the effect became more pronounced over time. It is possible
that we might identify a significant effect of TNF 238GrA
with an extended follow-up period. The greater diagnostic ac-
curacy in the study by Nolan et al. [8] (by the use of radiological
assessments of body composition) may further explain the dif-
ferences between the results of the studies. Although there was
an association between lipoatrophy and variant alleles of APOC3,
the biological mechanism is unclear, and this association needs
to be confirmed in other patient populations before it can be
considered a true finding.
Longitudinal modeling represents a powerful approach to
quantitating the individual contribution of genetic factors and
effects of ART in the context of complex traits. We exploited
prospectively collected data consisting of 12600 lipid deter-
minations in 329 individuals, during a study period of 13 years.
This allowed us to evaluate the influence of the polymorphisms
in APOC3 and APOE as well as multiple intervening factors of
relevance to plasma lipid levels (age, sex, ethnicity, smoking
status, mode of HIV transmission, ART group, CD4 T cell
count, HIV viremia, BMI, fasting state, treatment with lipid-
lowering agents, and diabetes mellitus status). The study pa-
tients served as their own controls, through multiple changes
in ART and periods when ART was not used. This approach
was selected in response to the well-recognized dilemmas in ge-
netic association studies, which regard, particularly, the issues of
statistical power, phenotype definition, and the use of appropriate
statistical tools. We also attempted a conventional matched con-
trol analysis using a single time point, which proved underpow-
ered for identification of the genetic effects. Potential bias arising
from overrepresentation of subjects with high plasma lipid levels
seems unlikely, because we found that the frequency of deter-
minations was comparable in subjects with low and high plasma
lipid levels.
The relatively high frequency of variant alleles of APOE and
APOC3 might suggest a potential role for genetic testing before
initiation of ART. This merits formal evaluation in a random-
ized trial. For example, 27.7% of patients in this study were
carriers of variant alleles of APOE, 17.9% were carriers of all
3 variant alleles of APOC3, and 5.8% were carriers of both.
The genotyping of treatment-naive patients might be an effi-
cient method to determine the advisability of the administra-
tion of RTV-containing ART. Given the risk of hypertriglyc-
eridemia, it might be prudent to select an alternative ART
regimen for patients who have unfavorable genotypes.
SWISS HIV COHORT STUDY
The members of the Swiss HIV Cohort Study are M. Battegay,
E. Bernasconi, J. Bo¨ni, H. Bucher, P. Bu¨rgisser, S. Cattacin, M.
Cavassini, R. Dubs, M. Egger, L. Elzi, P. Erb, K. Fantelli, M.
Fischer, M. Flepp, A. Fontana, P. Francioli (president), H. Furrer
(chairman of the Clinical and Laboratory Committee), M. Gor-
gievski, H. Gu¨nthard, B. Hirschel, L. Kaiser, C. Kind, T. Klim-
kait, U. Lauper, B. Ledergerber, M. Opravil, F. Paccaud, G.
Pantaleo, L. Perrin, J.-C. Piffaretti, M. Rickenbach (head of the
Data Center), C. Rudin (chairman of the Mother and Child
Substudy), P. Schmid, J. Schu¨pbach, R. Speck, A. Telenti, A.
Trkola, P. Vernazza (chairman of the Scientific Board), R. We-
ber, and S. Yerly.
References
1. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral
therapy and the risk of myocardial infarction. N Engl J Med 2003;
349:1993–2003.
2. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body
fat distribution in HIV-infected persons treated with antiretroviral
drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr
2002; 31:50–5.
3. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Coo-
per DA. Diagnosis, prediction, and natural course of HIV-1 protease-
inhibitor–associated lipodystrophy, hyperlipidaemia, and diabetes mel-
litus: a cohort study. Lancet 1999; 353:2093–9.
4. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected
1426 • JID 2005:191 (1 May) • Tarr et al.
patients receiving combination antiretroviral therapy: are different an-
tiretroviral drugs associated with different lipid profiles? J Infect Dis
2004; 189:1056–74.
5. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid trans-
port protein. Annu Rev Genomics Hum Genet 2000; 1:507–37.
6. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T.
Common genetic variation in the promoter of the human apo CIII
gene abolishes regulation by insulin and may contribute to hypertri-
glyceridemia. J Clin Invest 1995; 96:2601–5.
7. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An
apolipoprotein CIII haplotype protective against hypertriglyceridemia
is specified by promoter and 3′ untranslated region polymorphisms.
Proc Natl Acad Sci USA 1993; 90:4562–6.
8. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor–a gene
238G/A promoter polymorphism associated with a more rapid onset
of lipodystrophy. AIDS 2003; 17:121–3.
9. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M.
TNF-a promoter region gene polymorphisms in HIV-positive patients
with lipodystrophy. AIDS 2002; 16:2013–8.
10. Bastard JP, Caron M, Vidal H, et al. Association between altered ex-
pression of adipogenic factor SREBP1 in lipoatrophic adipose tissue
from HIV-1–infected patients and abnormal adipocyte differentiation
and insulin resistance. Lancet 2002; 359:1026–31.
11. Lister RK, Youle M, Nair DR, Winder AF, Rustin MH. Latent dys-
betalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet
1999; 353:1678.
12. Grunfeld C, Doerrler W, Pang M, Jensen P, Weisgraber KH, Feingold
KR. Abnormalities of apolipoprotein E in the acquired immunodefi-
ciency syndrome. J Clin Endocrinol Metab 1997; 82:3734–40.
13. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo
C-III variants and protease inhibitors contributes to high triglyceride/
low HDL levels in treated HIV patients. AIDS 2001; 15:2397–406.
14. Behrens G, Schmidt HH, Stoll M, Schmidt RE. ApoE genotype and
protease-inhibitor–associated hyperlipidaemia. Lancet 1999; 354:76.
15. Bonnet E, Ruidavets JB, Tuech J, et al. Apoprotein c-III and E-con-
taining lipoparticles are markedly increased in HIV-infected patients
treated with protease inhibitors: association with the development of
lipodystrophy. J Clin Endocrinol Metab 2001; 86:296–302.
16. Groenendijk M, Cantor RM, Blom NH, Rotter JI, de Bruin TW, Dal-
linga-Thie GM. Association of plasma lipids and apolipoproteins with
the insulin response element in the apoC-III promoter region in fa-
milial combined hyperlipidemia. J Lipid Res 1999; 40:1036–44.
17. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein
E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31:
545–8.
18. Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia
and the metabolic syndrome after an episode of hypertriglyceridemia
during 13-cis retinoic acid therapy for acne: a pharmacogenetic study.
Ann Intern Med 2002; 136:582–9.
19. Zeger SL, Liang KY. Longitudinal data analysis for discrete and con-
tinuous outcomes. Biometrics 1986; 42:121–30.
20. Diggle PJ. Analysis of longitudinal data. Oxford: Oxford University
Press, 2002.
21. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids
and post-heparin lipase activities in normal subjects. AIDS 2000; 14:
51–7.
22. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of
HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;
15:1389–98.
23. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-
infected individuals treated with protease inhibitors. The Swiss HIV
Cohort Study. Circulation 1999; 100:700–5.
24. Ware JH, Dockery DW, Louis TA, Xu XP, Ferris BG Jr, Speizer FE.
Longitudinal and cross-sectional estimates of pulmonary function de-
cline in never-smoking adults. Am J Epidemiol 1990; 132:685–700.
25. Ware JH. Linear models for the analysis of longitudinal studies. Am
Stat 1985; 39:95–101.
26. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials
to model continuous risk variables in epidemiology. Int J Epidemiol
1999; 28:964–74.
27. Royston P, Altman DG. Regression using fractional polynomials of
continuous covariates. Appl Stat 1994; 43:429–67.
28. Battino M, Giunta S, Galeazzi L, et al. Coenzyme Q10, antioxidant
status and ApoE isoforms. Biofactors 2003; 18:299–305.
29. Doser N, Sudre P, Telenti A, et al. Persistent dyslipidemia in HIV-
infected individuals switched from a protease inhibitor–containing to
an efavirenz-containing regimen. J Acquir Immune Defic Syndr 2001;
26:389–90.
